Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALBIREO PHARMA, INC.

(ALBO)
  Bericht
Verzögert Nasdaq  -  22:00:00 03.02.2023
44.95 USD   +0.90%
20.01.Insiderverkauf: Albireo Pharma
MT
20.01.HBM Healthcare bleibt nach 9 Monaten in der Verlustzone
AW
11.01.Albireo Pharma, Inc. : Guggenheim gibt eine neutrale Bewertung ab
MM
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ALBIREO PHARMA, INC.
24.01.Albireo Pharma Investor Alert By The : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
20.01.Insider Sell: Albireo Pharma
11.01.North American Morning Briefing: Stock Futures -2-
11.01.Albireo Pharma Investor Alert By The : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
10.01.North American Morning Briefing: More Hawkish Fed -2-
09.01.Top Midday Gainers
09.01.Albireo bondit après l'annonce de son rachat par Ipsen
09.01.Ipsen va acquérir Albireo pour un montant qui pourrait approcher 1,2 md de dollars
09.01.Sector Update: Health Care Stocks Mixed Pre-Bell Monday
09.01.Top Premarket Gainers
09.01.Ipsen va acquérir Albireo pour un montant qui pourrait dépasser 1,1 md de dollars
09.01.Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatme..
09.01.Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosur..
09.01.Albireo Pharma to be Acquired by Ipsen
09.01.Il en faut peu pour être heureux
09.01.Bolsa de Madrid: No hace falta mucho para ser feliz
09.01.France's Ipsen Moves to Broaden Rare Disease Portfolio Via $952 Million Purchase of Alb..
09.01.En direct des marchés : Orange, Dassault Systèmes, Euroapi, Elis, ..
09.01.AstraZeneca boosts heart, kidney business with $1.8 bln CinCor deal
09.01.Ipsen va acquérir Albireo pour un montant initial de 952 millions de dollars
09.01.Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatme..
09.01.Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Al..
2022Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022Albireo Pharma Submits Applications for Second Bylvay Indication in US, Europe
2022Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
2022Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and ..
2022Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D.,..
2022Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure..
2022Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., t..
2022Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson ..
2022Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (..
2022Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (..
2022Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
2022Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
2022Albireo to Participate in Jefferies London Healthcare Conference
2022Albireo Pharma Swings to Q3 Loss, Revenue Rises; Shares Drop
2022ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
2022Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
2022Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $9.8M, vs. Street Est of $9.54M
2022Albireo Reports Q3 2022 Financial Results and Business Update
2022Albireo Pharma, Inc. - Bylvay Data Presented at AASLD The Liver Meeting 2022, Demonstra..
2022Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Nat..
2022Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liv..
2022Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay in Biliary Atresia
2022Albireo Announces 2022 SPARK Grant Winners
2022Albireo Pharma Completes Patient Enrollment in Phase 3 Trial for Biliary Atresia Treatm..
2022Albireo to Present Late Breaking Bylvay Data at AASLD 2022
2022Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
2022Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary At..
2022Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
2022Albireo Pharma, Inc. to Present Late Breaking Bylvay Data at AASLD 2022
2022Albireo to Report Q3 2022 Financial Results on November 8, 2022
2022Albireo annuncia i risultati cardine dello studio di Fase 3 di Bylvay® (odevixibat) nel..
2022Albireo annonce des données clés positives à l'issue de la phase III sur Bylvay® (odevi..
2022Albireo informa de datos positivos de primera línea del ensayo de fase 3 sobre Bylvay® ..
2022Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay Treatment at NASP..
2022Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NAS..
2022Albireo Pharma, Inc. Presents Data on Greater Efficacy in PFIC with Earlier Bylvay Trea..
2022Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay in Alagille Syndrome
2022Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
2022Health Care Up Slightly As Amgen Rallies -- Health Care Roundup
2022Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
2022Albireo Pharma Says Late-Stage Trial of Bylvay for Alagille Syndrome Meets Primary Endp..
2022Albireo Pharma, Inc. : Results of Operations and Financial Condition, Other Events, Financ..
2022Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Ala..
2022Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Ala..
2022Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® in Ala..
2022Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
2022Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
2022Albireo Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
2022Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022Albireo Pharma Secures $115 Million Funding From Sagard Healthcare Partners for Liver D..
2022Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosur..
2022Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
2022Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
2022Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Biote..
2022Albireo Pharma Says Italian Regulator Approves Reimbursed Access to Bylvay to Treat Liv..
2022L'Agenzia Italiana del Farmaco approva il rimborso di Bylvay® (odevixibat) per i pazien..
2022Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patient..
2022Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of..
2022Albireo to Participate in Upcoming Investor Conferences
2022Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022Albireo Pharma : Management Change/Compensation - Form 8-K/A
2022ALBIREO PHARMA, INC. Change in Directors or Principal Officers (form 8-K/A)
2022Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Termination of a Materi..
2022ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
2022Albireo Pharma Q2 Loss Widens, Revenue Increases; Shares Sink After Hours
2022Albireo Pharma : Reports Q2 2022 Financial Results and Business Update - Form 8-K
2022Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $8.2M
2022Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $8.2M, vs. Street Est of $9.52M
2022Albireo Reports Q2 2022 Financial Results and Business Update
2022Albireo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months End..
2022North American Morning Briefing: Stock Futures -2-
2022Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure..
2022Albireo Pharma : Appoints New Members to Board of Directors - Form 8-K
2022Albireo Appoints New Members to Board of Directors
2022Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its..
2022Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
2022Albireo to Report Q2 2022 Financial Results on August 15, 2022
Anstehende Termine für ALBIREO PHARMA, INC.